Oncolytic Virus Therapy Market Poised for Rapid Expansion as Precision Immunotherapy Advances
核心洞察
The global oncolytic virus therapy market is projected to grow from USD 21.54 million in 2025 to USD 223.5 million by 2035, at a CAGR of 26.36% during 2026–2035.
Oncolytic viruses selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses, transforming "cold" tumors into "hot" ones.
A robust clinical pipeline, including cretostimogene grenadenorepvec, CAN-2409, RP1, and Olvi-Vec, is advancing across melanoma (搜索), bladder, lung, and other solid tumors.
The oncolytic virus cancer therapy market is entering a period of rapid expansion, driven by advances in genetically engineered viruses that selectively target and destroy cancer cells while stimulating broader anti-tumor immune responses. According to a research report published by Spherical Insights & Consulting, the global oncolytic virus therapy market is projected to grow from USD 21.54 million in 2025 to USD 223.5 million by 2035, at a compound annual growth rate (CAGR) of 26.36% during the forecast period 2026–2035. DelveInsight's market analysis similarly reports that the market size for oncolytic virus cancer therapy reached USD 177 million in the 7MM (the US, EU4, UK, and Japan) in 2025, with the United States accounting for the largest share.
Oncolytic virus therapy represents an advanced form of cancer immunotherapy that employs genetically engineered or naturally occurring viruses to selectively infect, replicate within, and destroy cancer cells while sparing most normal tissues. Once inside a tumor cell, the virus multiplies until the cancer cell ruptures, releasing newly formed viral particles that infect neighboring malignant cells. At the same time, the destruction of tumor cells exposes cancer-specific antigens to the immune system, stimulating a broader anti-tumor immune response. This dual function—direct tumor destruction combined with immune activation—distinguishes oncolytic virus therapy from many conventional cancer treatments.
A Maturing Clinical Pipeline
A diverse range of oncolytic virus platforms is currently under investigation, including adenoviruses, herpes simplex viruses, Maraba viruses, measles viruses, Newcastle disease viruses, picornaviruses, reoviruses, vaccinia viruses, and vesicular stomatitis viruses. The expanding clinical pipeline includes therapies such as cretostimogene grenadenorepvec (CG Oncology), CAN-2409 (Candel Therapeutics), AdAPT-001 (EpicentRx), LOAd703 (Lokon Pharma), RP1 (Replimune), VG 161 (Virogin Biotech), RP2 (Replimune), BS001 (Binhui Bio), Olvi-Vec (Genelux), CF33 (Imugene), BT-001 (BioInvent (搜索)/Transgene), TG6050 (Transgene), and pelareorep (Oncolytics Biotech).
Oncolytic virus therapies are primarily being developed to treat cancers in relapsed or refractory settings. Consequently, these therapies could address nearly 20% of all cancer cases, providing a significant treatable patient pool. The report covers top indications including melanoma (搜索), biliary tract cancer, head and neck cancer, pancreatic cancer (搜索), non-small cell lung cancer (搜索) (NSCLC), hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, and ovarian cancer (搜索).
Regulatory Milestones and Clinical Progress
The field has reached several notable regulatory milestones. In 2015, IMLYGIC became the first oncolytic virus to receive U.S. FDA approval for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma (搜索) that had recurred following initial surgery. Subsequently, in June 2021, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) obtained conditional and time-limited approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with malignant glioma (搜索).
More recently, in August 2026, Replimune Group (搜索), Inc. announced that the FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma (搜索) whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen.
In July 2026, UroGen Pharma Ltd. announced that the FDA cleared its Investigational New Drug (IND) application for UGN-501, a next-generation investigational oncolytic virus, paving the way for a planned Phase 1 clinical trial in patients with non-muscle invasive bladder cancer (搜索) (NMIBC).
Advancing Candidates Across Tumor Types
Several candidates are advancing through late-stage development. CG Oncology's cretostimogene is an investigational oncolytic immunotherapy administered intravesically, studied in the Phase III BOND-003 trial for patients with Bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), and evaluated as monotherapy in the Phase III PIVOT-006 trial for intermediate-risk NMIBC. The U.S. FDA has granted both Fast Track Designation and Breakthrough Therapy Designation to cretostimogene grenadenorepvec for the treatment of high-risk, BCG-unresponsive NMIBC with carcinoma in situ.
In May 2026, CG Oncology reported positive Phase II CORE-008 Cohort CX results, with cretostimogene grenadenorepvec plus gemcitabine demonstrating encouraging high-grade event-free survival (HG-EFS), high complete response (CR) rates, and favorable tolerability in high-risk NMIBC patients. In February 2026, the company reported accelerated enrollment and an expedited Phase III (PIVOT-006) timeline in intermediate-risk NMIBC, with topline data expected in 1H26, and remains on track for a BLA submission in high-risk BCG-unresponsive NMIBC during 2026.
Genelux's Olvi-Vec is a genetically modified vaccinia virus with a triple mechanism of action: it directly targets and destroys cancer cells, activates a tumor-specific immune response, and transforms the tumor microenvironment from an immunosuppressive "cold" state into an immunoreactive "hot" state. The therapy is under clinical development for platinum-resistant/refractory ovarian cancer (搜索), recurrent NSCLC, small cell lung cancer (SCLC), and pancreatic cancer (搜索). In November 2023, Genelux announced that the U.S. FDA granted Fast Track Designation to Olvi-Vec for platinum-resistant/refractory ovarian cancer. In March 2026, the company reported positive clinical progress, with Phase III ovarian cancer topline data expected in 2H26.
BioInvent (搜索)/Transgene's BT-001 is an oncolytic virus engineered to deliver BioInvent's anti-CTLA-4 (搜索) antibody directly within tumors, designed to enhance tumor-targeted activity while potentially reducing systemic side effects. The candidate is being investigated in combination with pembrolizumab in a Phase 1/2a clinical trial.
In June 2026, Candel Therapeutics initiated the global pivotal Phase 3 AURORA trial (NCT07660094) to evaluate aglatimagene besadenovec (CAN-2409) plus valacyclovir alongside continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC who experienced disease progression following pembrolizumab and platinum-based chemotherapy.
Drivers and Challenges
Several factors are accelerating adoption of oncolytic virus therapy. The rising global cancer burden continues to create demand for innovative treatment options capable of improving long-term survival while reducing treatment toxicity. Effective therapies for gastrointestinal cancers remain scarce, with less than 12% of pancreatic cancer (搜索) patients surviving beyond five years with the current standard of care. Growing demand for precision medicine, rapid advances in viral engineering, expanding combination therapy research, and increasing biotechnology investment are further supporting market growth.
Aparna Thakur, an oncology expert at DelveInsight, said that with ongoing advancements and strategic collaborations, oncolytic viruses are positioned to play a pivotal role in the future of oncology, providing patients with new hope and facilitating the development of more effective and personalized cancer therapies.
Despite this momentum, challenges remain. Large-scale manufacturing of genetically engineered viruses requires highly specialized production facilities and strict quality control standards. Regulatory pathways for complex biologic therapies remain rigorous, requiring extensive clinical evidence to demonstrate long-term safety and effectiveness. Additionally, pre-existing immunity against certain viral platforms may reduce therapeutic effectiveness in some patients by eliminating the virus before it reaches tumors.
Artificial intelligence is increasingly being integrated into viral engineering and biomarker discovery, helping researchers identify optimal viral modifications, predict patient responses, and accelerate clinical development. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the oncolytic virus cancer therapy market landscape, offering new standards of care and unlocking opportunities for medical innovation.